Concarlo Therapeutics (also known as Concarlo Holdings) is a precision-medicine oncology company focused on diagnosing and treating cancer. It directly drugs the p27 protein which controls CDK4/6/2 activity developing new treatments for a wide range of advanced and drug-resistant cancers.